Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.65 |
| ▸ | FYN | P06241 | 2/20 | 0.65 |
| ▸ | PIP4K2A | P48426 | 3/20 | 0.61 |
| ▸ | PIP4K2B | P78356 | 3/20 | 0.61 |
| ▸ | XDH | P47989 | 2/20 | 0.57 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.57 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191864 | 0.90 | BRAF (0.70) | BRAFFYNPIP4K2APIP4K2BXDH | |
| SCHEMBL4194092 | 0.88 | BRAF (0.65) | BRAFFYNPIP4K2APIP4K2BXDH | |
| SCHEMBL4198997 | 0.85 | BRAF (0.72) | BRAFFYNPIP4K2APIP4K2BXDH | |
| SCHEMBL4187619 | 0.85 | BRAF (0.62) | BRAFFYNPIP4K2APIP4K2BXDH | |
| SCHEMBL4185535 | 0.85 | XDH (0.61) | BRAFFYNPIP4K2APIP4K2BXDH | |
| SCHEMBL4191838 | 0.84 | BRAF (0.61) | BRAFFYNPIP4K2APIP4K2BXDH | |
| SCHEMBL4183190 | 0.84 | BRAF (0.71) | BRAFFYNPIP4K2APIP4K2B | |
| SCHEMBL4194542 | 0.83 | BRAF (0.62) | BRAFFYNPIP4K2APIP4K2BSMN1; SMN2 | |
| SCHEMBL4196452 | 0.83 | BRAF (0.59) | BRAFFYNPIP4K2APIP4K2BSMN1; SMN2 | |
| SCHEMBL4191746 | 0.82 | BRAF (0.68) | BRAFFYNPIP4K2APIP4K2BXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | claimed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | disclosed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | BRAF 3225/4885FYN 3292/4885PIP4K2A 748/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | BRAF 3225/4885FYN 3292/4885PIP4K2A 748/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | BRAF 3225/4885FYN 3292/4885PIP4K2A 748/4885 |
| US-20090196912-A1 | Pyridinylamines | PRNP, PLPBP, SNCA | BRAF 1471/4885FYN 173/4885PIP4K2A 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.